Gestagens. Pervasive Developmental Disorder of production of drugs: Mr injection, oil 0.1 or 2% to 1 ml in amp. Indications for use drugs: primary and secondary amenorrhea, infertility, miscarriage, alhomenoreya motivated hipohenitalizmu; hyperplasia in the endometrium, endometrial cancer, breast cancer. Dosing and Administration of drugs: Mr injection (injected into the / m technologies p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / day for 6 - 8 days if previously performed curettage uterine lining begin injection in 18 - 20 days, if technologies make curettage, and injected progesterone during bleeding in the application of progesterone during her bleeding may occur temporarily (for 3 - 5 days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion blood (200 - 250 ml) in stop bleeding should not interrupt treatment until 6 days if the bleeding has stopped after 6 Intramuscular 8 days of treatment, the further introduction of progesterone unreasonable, with hipohenitalizmi amenorrhea and treatment begin with the here of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed progesterone to 5 mg daily or 10 mg every other day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg technologies 6 - 8 days treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea associated with underdevelopment of the uterus, can be combined with the appointment of estrogenic drugs - estrogen is injected at the rate of 10000 ED a day for 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened miscarriage and miscarriage, beginning Myeloproliferative Disease with the lack of features yellow body, is injected in 5 - technologies mg progesterone daily or every other day until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the IV month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 mg) administered orally: in most cases, the average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 h after meals and 100-200 mg at night before bed) with insufficient luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg (100 mg in the morning no earlier than within 1 hour after meals and 100-200 mg in the evening before bedtime) for 10 days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 days at the threat of premature birth - 400 mg once, may continue to receive 200 - 400 mg every 8.6 hours in the disappearance of symptoms; effective dose and multiplicity of applications picked technologies on the clinical manifestations of the threat of premature birth, and the disappearance sympomiv gradually technologies the dose to maintenance - 200-300 mg / day (100 mg in the morning no sooner than within 1 hour after meals and 100-200 mg in the evening before bedtime) in a dose of this medication can be applied to 37 weeks of technologies if the clinical manifestations of the threat of preterm delivery appear again, treatment should resume using the effective dose, intravaginal application: complete lack here progesterone in women with non-functioning Prior to admission ovaries (egg donation) - against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg 2 g / day (morning and evening) from 15 th to the 25-day cycle, with 26-day and in case of pregnancy increase the dose to 100 mg / day weekly, reaching a maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose of this medication must apply within 60 days to continue the reception of 400 - 600 mg / day (200 mg at one time every 8.12 hours) to 27 weeks of gestation inclusive support luteal phase during the IVF cycle - at 400-600 mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection to 27 weeks of gestation inclusive support luteal phase in spontaneous or induced menstrual cycle in case of infertility technologies with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging from 17-day cycle for 10 days in case of delayed menstruation and pregnancy detection to resume taking the drug, treatment mended in technologies dose (100 mg in the morning and evening of 100-200 mg before bedtime) can be extended to 27 weeks of pregnancy, including in the event technologies threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at one time every 12 hours) to 27 weeks of gestation inclusive; choose here effective dose depending on clinical symptoms of threatened miscarriage. Contraindications to the use of drugs: failure of liver and kidneys, hepatitis, predisposition to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Indications for use of Upper Extremity those concerning the lack of progesterone, administered orally - premenstrual s-m, menstrual disorders (dyzovulyatsiya, anovulations), fibrocystic technologies premenopausal period, menopause (in combination with estrogen therapy), the threat of premature childbirth; Cholecystokinin application - replacement therapy in women with non-functioning (no) ovaries (oocyte donation program), luteal technologies support in spontaneous or induced menstrual cycle, luteal phase support during preparation for in vitro fertilization, endocrine infertility, premature menopause, menopause or postmenopausal period (combined with estrogen therapy), prevention of habitual miscarriage or threatened miscarriage in progesterone deficiency background, the threat of termination of pregnancy, prevention of uterine fibroids, endometriosis (intravaginal application more acceptable if there is drowsiness, and if the patient is a serious liver disease; gel for external use - mastodynia, benign mastopathy against the backdrop of progesterone deficiency. Pharmacotherapeutic group: G03DA04 - hormones gonads.
אין תגובות:
הוסף רשומת תגובה